OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

i'm in too at this price - 17p

i came back in this morn on these. this year is a more important one than last for ox bio and they are in a better position financially aswell. not sure whether to view them as a long term or short term investment though. any ideas?

I'm out, I think this rise is temporary so take profits.

I think the downward momentum may resume & I want the money for TAD.

why do you think the downward momentum may resume apple?

No, I think it was well oversold and will bounce quickly, the momentum should take it back to 23p in the very short term, and there's newsflow to come in the second half so expect some more articles/tips and the price breaking through the 30p this yr. The value is very hard to pin point as there are no substantial earnings yet but any one of their prods could be worth hundreds of millions and most tipsters reckon on around 40p as fair value.

tbrooking66

I'm guessing, the downward momentum was very strong & it has had a profitable short term bounce back.

& as said, I want the money for TAD

TAD may be much better in the short term if the rumoured news does come tomorrow.

I'll be back if OXB goes down again.

i think i'll stay with ox bio as i agree with robstuff.

As I thought, the rise was temporary.

BUT I was too cautious & got out a little bit too early.

I suppose it will go up again on next news & if it drops again 1st then I will get back in.

I looked at the trades this morning

& I'm back in just in time for a 10% rise, very nice.

Not sure how far it will go this time or why there was so much interest in it today.

RNS Number:1188Y
Oxford Biomedica PLC
29 April 2004

FOR IMMEDIATE RELEASE 29 APRIL 2004


OXFORD BIOMEDICA GAINS FDA APPROVAL
FOR A PHASE II TRIAL OF TROVAX(R) IN RENAL CANCER

- Patient Recruitment to Commence Q3 2004-


Oxford, UK: 29 April 2004 - Oxford BioMedica (LSE:OXB.L), the leading gene
therapy company, announces today that the US Food & Drug Administration (FDA)
has approved an Investigational New Drug (IND) application to evaluate
TroVax(R), the Company's proprietary cancer vaccine, in patients with metastatic
renal cancer.

TroVax(R) will be tested in combination with the standard treatment interleukin-
2 (IL-2), an immune stimulator, in patients whose median survival is
approximately 13 months. Safety and immunogenicity will be the primary goals,
but patients will be monitored for clinical benefit including increased
survival. The trial will be conducted at the Columbia Presbyterian Medical
Center in New York and patient recruitment is expected to start in Q3 2004. The
study should be complete, as far as the primary end-points are concerned, within
approximately twelve months of initiation.

There were an estimated 31,900 new cases of renal cancer in the US in 2003
(source: American Cancer Society, Cancer Facts and Figures for 2003). More than
half of these patients have metastatic disease (secondary cancer). After
surgical removal of the primary tumour, treatment with IL-2 has been shown to
have some benefit, suggesting that the tumours may be responsive to
immunological strategies. The rationale for this trial is that the immune
response induced by TroVax(R) may halt or delay the progression of metastases so
increasing survival beyond the estimated median of 13 months. Using TroVax(R) in
combination with IL-2 may enhance that response.

There is a great need for additional therapies for renal cancer as the prognosis
for patients is poor with current treatments. The regulatory strategy for the
development of TroVax(R) will involve seeking fast track approval and opening
discussions about product registration if early data are encouraging.

Commenting on the approval Oxford BioMedica's Chief Executive, Professor Alan
Kingsman said:

"We are delighted to be able to take TroVax(R) into the USA in an indication
that has real unmet medical need. We expect patient recruitment to be faster
than we have seen in previous trials and we are excited about testing TroVax(R)
with an immune stimulator such as IL2."

Excellent news ! FDA APPROVAL !!!!!!!!!!!!!!!

I particularly like this part :

"The regulatory strategy for the development of TroVax(R) will involve seeking fast track approval and opening discussions about product registration if early data are encouraging."

I wonder how fast "fast track approval" will be.

When this company gets just 1 of its drugs on the market, it will no longer be a penny share.

Any one with level 2 please. Looking to fill ISA

Just after I posted my last message, I saw it begin to fall again so I got out.

Good news has made it fall again.

Oh well 5% profit since Monday.

Keep dropping & I'll be back again.

At this level, looks like it may be time to get back in again.

Why should the appointment of Nick Rogers as senior director cause the price to be marked lower?

apple my thoughts exactly bought a nice chunk when saw price fall more than 10%.
This company is a gem with such huge potential, at these prices it's a steal.

robstuff new appointment and fall in sp not related. OXB being over done as is the case in these market conditions unfortunately but as noted above great buying opportunity.

Hmmmmm, I keep getting lucky with this share.

I was right yesterday, when I said it may be time to get back in again.

Nice profit since yesterday but I think it is time to sell again.

Fallen back again since I sold.

This seems to be my lucky share.

Of course now that I've said that, it will prove me wrong & shoot up again.

Maybe this time I sold too early but a profit is a profit.